If blood cell counts are low, then the drug given by the doctor is termedas a blood cell growth factor to stimulate the blood cell production. The body normally makes blood cell with the help of a hormone produced in the kidneys, called erythropoietin (EPO).
The DNA of immature blood cells, mainly white cells;get damaged in one way or the other. This abnormality causes the blood cell to grow and divided chaotically. Normal blood cells die after a while and are replaced by new cells that are produced in the bone marrow.
The abnormal blood cells do not die easily and accumulate, thereby occupying more space. As more space is occupied by these faulty blood cells there is less space for the normal cells and the patients take ill. Bad cells crowd over good cells in the blood
The Blood Cell Factor (Cancer supportive Care) Market size by different types of drugs: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim), along acting type (pegylated) of filgrastim called pegfilgrastim or Neulasta
Granulocyte-colony stimulating factor (G-CSF): Growth factors are also known as Colony stimulating factors. They are substances produced by the body and there are many different types. Some types stimulate the bone marrow to make certain blood cells. In cancer care, the treatment called Granulocyte Colony stimulating Factor (G-CSF) after chemotherapy the blood count is increased
Granulocyte macrophage-colony stimulating factor (GM-CSF): Researchers are looking into using some types of blood cell growth factors as biological therapy. GM-CSF (granulocyte and macrophage colony stimulating factor) is a growth factor that increases the number of some types of white blood cells (neutrophils and monocytes).
It also stimulates dendritic cells to divide. These are a type of white blood cell that helps the immune system to recognize and attack cancer cells. So researchers are using GM-CSF alongside the other biological therapies to try to boost numbers of dendritic cells and help them to work.
Researchers are also using GM-CSF in cancer vaccines for certain types of cancer. This is still experimental research. In trials so far, patients who had got these vaccines administered made more dendritic cells. However, we are yet to figure out whether this will affect their cancer. Trials have only been carried out with very small numbers of patients, mostly with advanced melanoma.
The Blood Cell Factor (Anemia), by different types of Treatments: Certain drugs including colony stimulating factors such as sargamostim (Leukine), filgrastim (Neupogen) and pegfilgrastim (Neulasta) and epoetin alfa (Epogen, Procrit) may help stimulate the bone marrow to produce new blood cells.
Nutritional supplements: Iron B12 or folic acid, treatment of infections, inflammations or malignancies, Erythropoietin, Blood transfusions providing red blood cell transfusions for bleeding and severe chronic anemias may be the quick relief of anemia.
Erythropoietin (Epoetin alfa): It is a hormone produced by kidney (90%) and 10% of liver in response to hypoxia or low oxygen levels,. The increased number of red cells helps to deliver more oxygen level to tissue and resolve symptoms of weakness.
Blood Cell Factors (cancer supportive care/Anemia) Market scenario by Geographical Region: North America, Asia-Pacific, Europe, and Rest of the World.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.